Đánh giá hiệu quả, tính an toàn của thuốc albendazol và ivermectin điều trị bệnh nhiễm ấu trùng giun đũa chó, mèo (ATGĐCM) ở người tại Khánh Hòa. Đối tượng và phương pháp: Nghiên cứu can thiệp, tiến cứu 100 bệnh nhân đủ tiêu chuẩn chẩn đoán ca bệnh nhiễm ATGĐCM. Trong 866 người xét nghiệm ngẫu nhiên dương tính với ELISA Toxocara spp. tại tỉnh Khánh Hòa. Sau 10 - 12 tháng 50 bệnh nhân uống thuốc albendazol 400 mg, liều 15 mg/kg/ ngày trong 14 ngày, 50 bệnh nhân uống ivermectin 3 mg liều 0,2 mg/kg trong 2 ngày liên tiếp, bệnh nhân được khám lâm sàng và xét nghiệm lại: CTM, ELISA Toxocara spp. Kết quả và kết luận: Thuốc albendazol 400 mg có tác dụng tốt hơn ivermectin 3 mg về mặt lâm sàng nhưng có tác dụng không mong muốn mức độ 1 và 2 (10%) so với ivermectin.
The clinical presentation of Toxocariasis is varied, making diagnosis and treatment challenging. It is crucial to assess the efficacy and safety of medication to select an appropriate treatment regimen. Objectives: Evaluating the effectiveness and safety of Albendazol and Ivermectin to treat dogs and cats Toxocara worm infection in humans, Khanh Hoa Province. Subjects and methods: Prospective and interventional study. A randomized, controlled intervention study was conducted to treat Toxocariasis (visceral Larva migrans) with two types of drugs albendazol and Ivermectin, in three socio-geographical regions of Khanh Hoa province from March 2023 to December 2023. Among 866 cases tested positive with ELISA IgG spp., 100 patients were randomly selected and divided into 2 groups, each consisting of 50 individuals, following two treatment protocols using ivermectin and albendazol. Clinical standards and drug dosages were based on the treatment protocol for Toxocariasis issued by the Ministry of Health. The follow-up period was 10 - 12 months. Results: There was a statistically significant difference in clinical symptoms, ELISA, Eosinophil values before and after treatment. There was no statistically significant difference in clinical symptoms before being divided into 2 groups. There was a statistically significant difference in clinical symptoms: Itching, headache, numbness after treatment between the albendazol and Ivermectin groups. No statistically significant difference: ELISA, Eosinophil, hemoglobin, Platelet values after treatment between the albendazol and ivermectin groups. albendazol treatment for Toxocariasis infection had adverse effects (10%) at levels 1 and 2. Conclusions: Albendazol is the drug of choice to treat dog and cat roundworm larvae infections because of its effectiveness and low unwanted effects (10%).
- Đăng nhập để gửi ý kiến